From Nasdaq: 2025-06-07 08:44:00

Lars Fruergaard Jørgensen steps down as CEO of Novo Nordisk after leading the company to a 304% return since January 2017. Recent struggles include a nearly 52% stock decline and losing market share to Eli Lilly. Novo’s experimental weight loss drug results fell short, leading to Jørgensen’s departure.

Novo Nordisk’s market share has fallen from 71% to 55% due to successful sales of Lilly’s weight loss drugs. Novo’s CagriSema drug trials disappointed investors, causing share prices to drop. Lilly’s oral GLP-1 for diabetes met expectations, leading to a rise in shares. Lilly’s stock has declined less than Novo’s since June 2024.

Novo Nordisk is expected to hire an external CEO, potentially an American, to navigate U.S. market challenges. The next CEO must revitalize the drug pipeline to compete with Lilly. Novo relies heavily on U.S. sales, making an American CEO a strategic choice despite potential internal issues.

Novo Nordisk faces uncertainty as it awaits August earnings. Missteps have allowed Lilly to catch up in the GLP-1 market. Novo’s future plans and stock evaluation will be clearer after the earnings report. Investors are advised to stay informed on market trends and analyst recommendations. 1. Novo Nordisk, a pharmaceutical company listed on the NYSE under the ticker symbol NVO, reported a 4% increase in operating profit for the second quarter of 2021, reaching $1.38 billion.

2. The company’s sales also saw a 9% growth, amounting to $5.7 billion, driven by strong performance in its diabetes and obesity care segments.

3. Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, credited the company’s innovative products and dedicated employees for the positive financial results and expressed confidence in continued growth.



Read more at Nasdaq:: With Novo Nordisk’s CEO Out, Wall Street Wants an American Leader